April 18 Product: Genentechs Alecensa Indication: Non-small cell lung cancer The FDA approved Genentechs Alecensa Thursday as the first adjuvant treatment for patients with early-stage, anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer who have undergone tumor resection
Systolic blood pressure improved
For simplicity, this Insight uses the term GLP-1 drugs to refer to both semaglutides and tirzepatides
In adjusted analyses, semaglutide reduced epigenetic aging across multiple second- and third-generation clocks, including PhenoAge ( 4.9 years/year, p = 0.004), PCGrimAge ( 3.1, p = 0.007), GrimAge V2 ( 2.3, p = 0.009), OMICmAge ( 2.2, p = 0.009), RetroAge ( 2.2, p = 0.030), and DunedinPACE ( 0.09 units, 9% slower, p = 0.01)
Good handling of these effects is crucial for securing improved health outcomes and continued treatment